HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo, Sanofi Look Far Afield For Consumer Health Growth

This article was originally published in The Pink Sheet

Executive Summary

Big pharmas' recent third-quarter results and commentaries point to sales drivers for consumer health divisions coming from markets outside their established primary markets of US and Europe. Consumer unit lines include oral care and topicals as well as nutritional products.

You may also be interested in...



GSK Invests In OTC Production, Prepares To Divest Horlicks Nutritional Business

Latest consumer health investment was $36m upgrade to a Canadian facility, which by mid-2019 will begin making Voltaren OTC topical gel products. GSK's next move in consumer health divestment is its pending sale of its Horlicks business.

Bayer’s Consumer Health Sales Stay Cool During Summer Months

Bayer reported consumer health sales globally fell 1.4% to $1.64bn after a late start to the allergy season drove down Claritin sales. Aleve analgesics sales grew 3.3% to $112.5m on US line extensions while Alka Seltzer line sales were flat at $47.5m.

Pfizer Deals Consumer Health Its Own Hand, Plays Waiting Game For Bids

By setting up Pfizer Consumer Healthcare to have sales and earnings results reported separately, pharma giant could be making the division's assets more visible to potential buyers. Its sales pitch: "With a strong portfolio of global brands that span health and wellness, the company believes this business is well positioned to continue its growth."

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel